Research Appraisals
Evidence-based critical appraisals of the latest medical research, systematically evaluated using Oxford CEBM methodology.
Showing 2 appraisals
PloS one
Emotion-focused therapy and forgiveness in the older population: Protocol for a feasibility randomized controlled trial
Over recent decades, Emotion-Focused Therapy, aging, and forgiveness have garnered significant attention in the field of psychology. However, there is a lack of studies on Emotion-Focused Therapy and forgiveness specifically tailored for older adults. This article presents a protocol designed to assess the feasibility and acceptability of a randomized controlled trial of Emotion-Focused Therapy aimed at resolving emotional injuries in individuals aged 65 and older, within the context of interpersonal offenses. Feasibility will be evaluated through recruitment and retention rates, as well as adherence to the intervention protocol. Acceptability will be assessed based on perceived treatment credibility, participants' expectations regarding outcomes, levels of engagement, and overall satisfaction with the intervention. The study is structured as a two-arm, parallel-group randomized trial with a waiting list control. We propose recruiting a sample of 70 participants, randomly assigned to either an immediate intervention group, which will receive Emotion-Focused Therapy over twelve weekly sessions, or a control group that will receive the same therapy after a twelve-week waiting period. Data will be collected in the beginning, middle, and at the end of therapy, and in two planned follow-ups (three and six months after therapy). Once this protocol is implemented, if the therapy proves to be feasible, acceptable, and shows promising results, the findings will inform a large-scale randomized clinical trial to advance the understanding of this treatment for individuals aged 65 + .
15 May 2026
Read appraisal →Journal of affective disorders
Plasma metabolomics identifies lipid mediators linking depression and cognitive decline in late-life depression.
BACKGROUND: Late-life depression (LLD) features recurrent episodes and frequently co-exists with cognitive impairment, which predicts worse outcomes and progression to dementia. Evidence indicates a bidirectional depression-cognition relationship, but objective biological tools to capture severity and this interplay are scarce. METHODS: This study compared 110 patients with LLD between depressive episodes and remission phases. Based on untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics analysis of plasma samples, we identified key metabolites and developed four predictive machine learning models (GLMNet, LDA, Naive Bayes, and cTree). Additionally, Spearman rank correlation analysis and mediation analysis were conducted to further investigate the relationships and mediating effects of the key metabolites. RESULTS: The diagnostic model based on key metabolites selected by the random forest algorithm showed good discriminatory performance in distinguishing LLD Episodes (AUC = 0.824). Tridecanoylcarnitine (Car(13:0)), PC(P-16:0/22:6), and SM(d18:1/22:0) were significantly downregulated during the depressive episode. Tridecanoylcarnitine (Car(13:0)) negatively correlated with depressive severity (p < 0.001) and positively with Mini-Mental State Examination scores. PC(P-16:0/22:6) was associated with both emotional and cognitive impairments. Mediation analysis supported that Tridecanoylcarnitine (Car(13:0)) and PC(P-16:0/22:6) partially mediated the depression-cognition relationship, explaining 22.0 % and 26.9 % of the variance, respectively (p < 0.05). CONCLUSION: This study reveals specific lipid metabolic dysregulation in LLD and identifies key metabolites significantly associated with both depressive severity and cognitive function. It further supports their mediating role in the comorbidity between depression and cognitive impairment. These metabolites may serve as potential targets for simultaneously regulating depression and cognition. The machine learning model developed provides a new auxiliary tool for the objective assessment of LLD.
4 May 2026
Read appraisal →